Please try another search
For the nine months ended 30 September 2020,BioSpecifics Technologies Corp. revenues decreased 6% to$24.8M. Net income decreased 42% to $10M. Revenues reflectRoyalties decrease of 14% to $22.8M. Net income alsoreflects General and administrative increase of 57% to$9.8M (expense), Interest income decrease of 23% to $1.1M(income), Stock based compensation G&A increase of 15% to$468K (expense).
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 11.26 | 3.9 | 9.67 | 11.76 |
Gross Profit | ||||
Operating Income | 6.51 | -0.25 | 5.23 | 8.96 |
Net Income | 5.39 | 0.12 | 4.5 | 7.35 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 137.27 | 133.78 | 133.25 | 126.65 |
Total Liabilities | 1.96 | 4.36 | 3.98 | 2.16 |
Total Equity | 135.31 | 129.42 | 129.27 | 124.49 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 16.44 | 14.83 | 8.22 | 22.29 |
Cash From Investing Activities | -18.22 | -2.6 | 6.14 | -32.03 |
Cash From Financing Activities | -0.35 | -0.35 | -0.22 | 1.57 |
Net Change in Cash | -2.13 | 11.87 | 14.14 | -8.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review